{
    "organizations": [],
    "uuid": "c18432bf80679f27144d8a2dc96d47234d79fa84",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-epigen-biosciences-says-enters-col/brief-epigen-biosciences-says-enters-collaboration-agreement-with-novo-nordisk-a-s-idUSFWN1SU0Z5",
    "ord_in_thread": 0,
    "title": "BRIEF-Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Novo Nordisk A/S:\n* EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION\n* EPIGEN BIOSCIENCES SAYS CO WILL ALSO BE ELIGIBLE TO GET TIERED ROYALTIES AND MILESTONES ON WORLDWIDE SALES OF PRODUCTS THAT ARISE FROM COLLABORATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-24T05:42:00.000+03:00",
    "crawled": "2018-05-24T20:25:27.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novo",
        "nordisk",
        "epigen",
        "bioscience",
        "say",
        "enters",
        "collaboration",
        "license",
        "lpa1",
        "receptor",
        "small",
        "molecule",
        "program",
        "novo",
        "nordisk",
        "usd",
        "million",
        "epigen",
        "bioscience",
        "say",
        "co",
        "also",
        "eligible",
        "get",
        "tiered",
        "royalty",
        "milestone",
        "worldwide",
        "sale",
        "product",
        "arise",
        "collaboration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}